Trial Profile
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Jun 2020
Price :
$35
*
At a glance
- Drugs Armodafinil (Primary) ; Corticosteroids
- Indications Fatigue
- Focus Therapeutic Use
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 05 Feb 2020 Status changed from active, no longer recruiting to completed.
- 14 May 2019 Status changed from recruiting to active, no longer recruiting.